David Einhorn - DME Capital Management,
Holding/activity history for Lakefront Biotherapeutics (LKFT)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 482,746 | 0.45 | $30.00 | $14,482,380 | SEC | ||
| 2025 Q4 | 482,746 | 0.55 | $32.70 | $15,785,794 | SEC | ||
| 2025 Q3 | 482,746 | 0.66 | $34.64 | $16,722,321 | SEC | ||
| 2025 Q2 | 482,746 | 0.58 | $27.99 | $13,512,060 | SEC | ||
| 2025 Q1 | 482,746 | 0.61 | Add 0.71% | <0.01 | $25.12 | $12,126,580 | SEC |
| 2024 Q4 | 479,363 | 0.68 | $27.50 | $13,182,483 | SEC | ||
| 2024 Q3 | 479,363 | 0.57 | Add 104.13% | 0.29 | $28.79 | $13,800,860 | SEC |
| 2024 Q2 | 234,828 | 0.28 | Add 46.93% | 0.09 | $24.78 | $5,819,038 | SEC |
| 2024 Q1 | 159,828 | 0.24 | $32.20 | $5,146,462 | SEC |